BLRX•benzinga•
Why Is Nano-Cap BioLineRx Stock Surging On Friday?
Summary
BioLineRx shares new data from its Phase 2 pancreatic cancer trial, showing strong response rates and durable outcomes with motixafortide combination.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 30, 2025 by benzinga